) The University of Colorado Comprehensive Cancer Center (UCCC) is the only NCI- designed comprehensive Cancer Center in the Rocky Mountain region which has a population of about 8 million. The goals are to: 1) contribute to the reduction and elimination of cancer as a human health problem through coordinated programs in basic, clinical, translational and population sciences and 2) provide the citizens of the Rocky Mountain region with state-of-the-art cancer research, clinical, prevention and control and education programs. There are 244 full and 82 associate members who participate in one or more of the UCCC's 10 program including Cell Biology, Molecular and Structural Biology, Immunology and Immunotherapy, Hormone Related Malignancies, Tobacco Related Malignancies, Developmental Therapeutics, Pediatric Oncology, Cancer Genetics, Carcinogenesis and Chemoprevention and Clinical and Community Cancer Prevention and Control. Over the past 5 years, programs were reorganized to foster collaborative and translational research by including elements of basic, clinical and population sciences into the programs and to respond to rapid changes in scientific technology. UCCC members' productivity has increased as documented by more grant funding (32%), by a phenomenal growth in accruals to clinical trials (>1000%) and by their publication record. Cancer focus also increased as shown by the increases in NCI and peer-reviewed cancer agency funding (36%), and the increase in cancer clinical trials noted above. The research of the members is supported by 15 shared core resources which include 4 new facilities (Gene Expression, NMR, Pharmacology, Survey Research), 9 cores with expanded services (Biostatistics, Clinical Investigations, Cytogenetics, Flow Cytometry, Laboratory Animals, Tissue Procurement, Radiological Sciences, Protein Microchemistry, and Transgenic/Knockout) and 2 cores with continued services utilized by increased number of members (DNA Sequencing and Tissue Culture/Monoclonal Antibody). Core usage has increased over the past 5 years as documented by number of members, units of use, and charge back fees generated (110% increase). We have emphasized new technologies in the creation and expansion of these services. The UCCC is a """"""""matrix"""""""" Center within the School of Medicine, but has members from all of the UCHSC schools and affiliated institutions. During the next 3 years the UCCC will relocate to the new Fitzsimons campus which will triple the available outpatient and clinical research space (Nov. 2000) and the basic research space (Nov. 2002) at a cost of more than $180 million.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-16S1
Application #
6785025
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1988-03-01
Project End
2006-01-31
Budget Start
2003-05-15
Budget End
2004-01-31
Support Year
16
Fiscal Year
2003
Total Cost
$400,000
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Collins, Keagan P; Jackson, Kristen M; Gustafson, Daniel L (2018) Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther 365:447-459
Villalobos, Victor Manuel; Hall, Francis; Jimeno, Antonio et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 25:768-775
Montford, John R; Lehman, Allison M B; Bauer, Colin D et al. (2018) Bone marrow-derived cPLA2? contributes to renal fibrosis progression. J Lipid Res 59:380-390
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Goodspeed, Andrew; Jean, Annie; Costello, James C (2018) A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol :
Niemeyer, Brian F; Oko, Lauren M; Medina, Eva M et al. (2018) Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis. J Virol 92:
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236

Showing the most recent 10 out of 1634 publications